

**GREENBONE SPA SIGNS AN AGREEMENT WITH *ABIOTEN PHARMA SPA* FOR THE DISTRIBUTION IN THE ITALIAN MARKET OF **b.BONE**<sup>™</sup>, ITS INNOVATIVE 3D BONE SUBSTITUTE FOR ORTHOPEDIC AND TRAUMA SURGERY**

GreenBone Ortho SpA, a leading innovator for orthopedic biomaterial, today announced that it has signed an agreement with *Abioten Pharma SpA* for the distribution in the Italian market of **b.Bone**<sup>™</sup>, its patented 3D bone regenerative scaffold derived from biomorphic transformation of Rattan wood.

Under the terms of the agreement, Abioten will employ its sales and marketing expertise to distribute b.Bone 3D bone substitute across all Italian territory.

"We are very excited about this agreement with Abioten – declares Diogo C. Moreira-Rato, Non Executive Board Member and former Johnson & Johnson Senior Executive - an Italian leader in the orthopedic market segment. We are confident that this agreement will lead not only to successful commercial results for b.Bone in the Italian market but will also be a driving force for the development of other European markets where GreenBone is focusing its efforts."

"The agreement with Abioten represents the successful completion of GreenBone efforts from lab to market – declares Lorenzo Pradella, Co-Founder of GreenBone Ortho SpA – transforming a brilliant innovative research into a commercially valuable product, thanks to our highly skilled team."

Millions of people have bone repair surgery to treat bone loss resulting from trauma, cancer or bone degenerative conditions. It normally requires multiple surgery with significant risks for patients and very high social and healthcare costs. Bone replacement options are: bone transplant (the best option today) or bone grafts (ceramic, polymer and metal alloys), but medical professionals are grappling with the limitations of existing solutions.

GreenBone innovative bone scaffold **b.Bone**<sup>™</sup> is a nature inspired solution designed to meet the highest standards in tissue engineered performance. **b.Bone**<sup>™</sup> 3D scaffold is a Rattan wood-derived highly porous biomimetic material. It mimics natural bone chemistry, morphology and 3D architecture. CE-mark has been granted in 2019 for a portfolio of solutions to serve a variety of orthopedic surgical needs with indication of use in orthopedic and trauma surgery, including large bone defects. More than 60 patients have been treated at April 2022.

New indications of use are under development including spine surgery.

The technology was conceived at the Institute of Science and Technology for Ceramics (ISTEC), part of the Italian National Research Council (CNR).



### **About GreenBone Ortho Spa:**

GreenBone Ortho SpA, is a highly innovative company in the field of bone regeneration founded in 2014, Faenza (Italy). GreenBone has recently established a second facility located in Roncadelle (Brescia) to develop bigger production capacity to serve international markets.

b.Bone™ proprietary 3D scaffold is biomimetic biomaterial from Rattan wood-derived materials – a nature inspired solution. This new generation highly porous graft mimics natural bone chemistry, morphology and 3D architecture. More than 60 patients treated at April 2022. European approval (CE-Mark) has been granted in Dec 2019 for a portfolio of solutions to serve a variety of orthopedic surgical needs. The company raised EURO 22 million equity investments. In 2021 a EURO 2.5 million grant from the EIC Accelerator program for the development of a new indication in spine fusion surgery.

to know more about GreenBone Ortho SpA: [www.greenbone.it](http://www.greenbone.it)

### **About Abiogen Pharma Spa:**

The history of Abiogen Pharma dates back to 1917, the year of the foundation of the Galenic Institute, then the Gentili Institute, by Commendatore Alfredo Gentili, but it was more recently, in 1997, when the family business was sold to Merck Sharp & Dhome, that Dr. Massimo Di Martino, great-grandson of the founder, constitutes Abiogen Pharma, through the re-acquisition of some assets. With the aim of keeping alive a hundred years of entrepreneurial commitment by the family, Abiogen Pharma maintains a part of the drug list, the staff, the structures, the Research Center and development projects. The company presents itself, and subsequently grows, nationally and internationally, with the aim of producing excellent drugs accessible to all, operating in four integrated areas of activity: research and development, production of own and third party drugs and marketing of proprietary and licensed drugs.

To know more about Abiogen Pharma Spa: [www.abiogen.it](http://www.abiogen.it)

### **Press Office Greenbone**

Cristina Maradini

P +39 02 8372322

E [cristina@realtamilano.it](mailto:cristina@realtamilano.it)